Dataset Information

Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy.

ABSTRACT:

Background

Cardiac resynchronization therapy (CRT) improves left ventricular (LV) volumes, mitral regurgitation (MR) severity and symptoms of patients with heart failure (HF). However, >or= 30% of patients have no significant clinical or echocardiographic improvement following CRT. Reverse remodeling after CRT correlates with improved clinical outcomes. We hypothesized that in NT-pro BNP monitoring is accurate to identify responders following CRT.

Methods

42 consecutive patients (mean age 66 +/- 12 years, male 68%) with HF undergoing CRT were prospectively enrolled. Responders at follow-up were defined by echocardiography (decrease in LV end systolic volume >or= 15%). Echocardiography and NT-pro BNP measurement were performed at baseline and repeated 3 to 6 month after CRT.

Results

There was no significant difference between responders (n = 29, 69%) and non-responders (n = 13, 31%) regarding baseline NT-pro BNP level. Responders had significantly higher decrease in NT-pro BNP levels during follow-up than non-responders (absolute: -1428 +/- 1333 pg x ml-1 vs. -61 +/- 959 pg x ml-1, p = 0.002; relative: -45 +/- 28% vs. 2 +/- 28%, p < 0.0001). A decrease of >or= 15% in NT-pro BNP 3-6 months after CRT identifies echocardiographic responders with a sensitivity of 90% and a specificity of 77%.

Conclusion

NT-pro BNP monitoring can accurately identify echocardiographic responders after CRT.

SUBMITTER: Magne J

PROVIDER: S-EPMC2744656 | biostudies-literature | 2009 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy.

Magne Julien J Dubois Michelle M Champagne Jean J Dumesnil Jean G JG Pibarot Philippe P Philippon François F O'Hara Gilles G Sénéchal Mario M

Cardiovascular ultrasound 20090820

<h4>Background</h4>Cardiac resynchronization therapy (CRT) improves left ventricular (LV) volumes, mitral regurgitation (MR) severity and symptoms of patients with heart failure (HF). However, >or= 30% of patients have no significant clinical or echocardiographic improvement following CRT. Reverse remodeling after CRT correlates with improved clinical outcomes. We hypothesized that in NT-pro BNP monitoring is accurate to identify responders following CRT.<h4>Methods</h4>42 consecutive patients ( ...[more]

PMID: 19695099

Similar Datasets

Project description:Background and aimsPlasma levels of NT-pro-BNP, a natriuretic peptide precursor, are raised in the presence of fluid retention of cardiac origin and can be used as markers of cardiac dysfunction. Recent studies showed high levels of NT pro BNP in patients with cirrhosis. We assessed NT pro-BNP and other parameters of cardiac dysfunction in patients with cirrhosis, with or without ascites, in order to determine whether the behaviour of NT pro BNP is linked to the stage of liver disease or to secondary cardiac dysfunction.MethodsFifty eight consecutive hospitalized patients mostly with viral or NAFLD-related cirrhosis were studied. All underwent abdominal ultrasound and upper GI endoscopy. Cardiac morpho-functional changes were evaluated by echocardiography and NT-pro-BNP plasma levels determined upon admission. Twenty-eight hypertensive patients, without evidence of liver disease served as controls.ResultsFifty eight cirrhotic patients (72% men) with a median age of 62 years (11% with mild arterial hypertension and 31% with type 2 diabetes) had a normal renal function (mean creatinine 0.9 mg/dl, range 0.7-1.06). As compared to controls, cirrhotic patients had higher NT pro-BNP plasma levels (365.2±365.2 vs 70.8±70.6 pg/ml; p<0.001). Left atrial volume (LAV) (61.8±26.3 vs 43.5±14.1 ml; p = 0.001), and left ventricular ejection fraction (62.7±6.9 vs. 65.5±4%,; p = 0.05) were also altered in cirrhotic patients that in controls. Patients with F2-F3 oesophageal varices as compared to F0/F1, showed higher e' velocity (0.91±0.23 vs 0.66±0.19 m/s, p<0.001), and accordingly a higher E/A ratio (1.21±0.46 vs 0.89±0.33 m/s., p = 0.006).ConclusionNT-pro-BNP plasma levels are increased proportionally to the stage of chronic liver disease. Advanced cirrhosis and high NT-pro-BNP levels are significantly associated to increased LAV and to signs of cardiac diastolic dysfunction. NT pro-BNP levels could hence be an useful prognostic indicators of early decompensation of cirrhosis.

Dataset Information

Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy.

Background

Methods

Results

Conclusion

Publications

Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets